# Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study

**Authors:** Qichen Wang, Sarah C. Van Alsten, Xiaojia Ji, Esraa Salim, Nicole Salazar, John E. Scott, Xiaohe Yang, Rob U. Onyenwoke, Melissa A. Troester, Kevin P. Williams

PMC · DOI: 10.1007/s10549-025-07884-3 · Breast Cancer Research and Treatment · 2026-01-22

## TL;DR

This study explores the molecular and socioeconomic features of inflammatory breast cancer, finding associations with race, age, and specific genetic pathways.

## Contribution

The study identifies novel socioeconomic and molecular associations specific to inflammatory breast cancer using a large dataset.

## Key findings

- IBC is associated with Black race, age under 50, rural residence, and poverty.
- IBC shows strong associations with HER2-enriched and Luminal B molecular subtypes.
- Only six genes were significantly differentially expressed in IBC, including HER2-related and P53-related genes.

## Abstract

Inflammatory breast cancer (IBC) has been hypothesized to represent a distinct molecular subtype. However, few IBC-specific gene expression patterns have been identified, and previous genomic studies of IBC have been small with limited information on social determinants.

We identified 153 IBC cases in the Carolina Breast Cancer Study (total N = 4,739). RNA expression was measured on the NanoString platform (N = 74 IBC, 2,696 non-IBC) and used to determine molecular subtypes, including PAM50, immune, homologous recombination deficiency (HRD), and P53 status. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) of associations between IBC and patient demographic, molecular, and social characteristics using logistic regression, and compared differences in gene expression using ANOVA.

Women with IBC were associated with Black and under 50 compared to non-IBC. IBC was associated with rural address (OR = 1.53) and poverty (OR = 1.61). Molecularly, IBC was associated with HER2-enriched (OR = 6.14), Luminal B (OR = 2.90), P53 Mutant-like (OR = 1.79), and high HRD (OR = 1.90). Neither adiposity nor immune subtype was significantly associated with IBC. Only six of 219 genes measured were significantly differentially expressed between IBC and non-IBC, including HER2-related (ERBB2, FGFR4, GRB7) and P53-related genes (BTG2, LOC400043, MAP2K4).

Although not associated with immune subtypes, IBC showed differences in HER2 and P53 pathways. The association of IBC with rurality and poverty underscores the importance of health care access for timely diagnosis and treatment of IBC.

The online version contains supplementary material available at 10.1007/s10549-025-07884-3.

## Linked entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064], FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264], GRB7 (growth factor receptor bound protein 7) [NCBI Gene 2886], BTG2 (BTG anti-proliferation factor 2) [NCBI Gene 7832], MAP2K4 (mitogen-activated protein kinase kinase 4) [NCBI Gene 6416]
- **Diseases:** inflammatory breast cancer (MONDO:0006804), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, BTG2 (BTG anti-proliferation factor 2) [NCBI Gene 7832] {aka APRO1, PC3, TIS21}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, LINC02381 (long intergenic non-protein coding RNA 2381) [NCBI Gene 400043] {aka HMS, lncEPAT}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, MAP2K4 (mitogen-activated protein kinase kinase 4) [NCBI Gene 6416] {aka JNKK, JNKK1, MAPKK4, MEK4, MKK4, PRKMK4}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, GRB7 (growth factor receptor bound protein 7) [NCBI Gene 2886], NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264] {aka CD334, JTK2, TKF}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}
- **Diseases:** edema (MESH:D004487), adiposity (MESH:D018205), inflammation (MESH:D007249), triple-negative (MESH:D064726), Breast Cancer (MESH:D001943), infection (MESH:D007239), erythema (MESH:D004890), obesity (MESH:D009765), HRD (MESH:C535296), (American Joint Committee on Cancer) (MESH:D009369), IBC (MESH:D058922)
- **Chemicals:** paraffin (MESH:D010232), formalin (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12827424/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12827424/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12827424/full.md

---
Source: https://tomesphere.com/paper/PMC12827424